DiagnoCure Retains JMP to Help with Lab Business
August 25, 2010
DiagnoCure Retains JMP to Help with Lab Business
The company's president noted that his firm and JMP Securities will work together to "determine the most effective method to roll out our colorectal cancer disease management program."
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Canada Approves Gen-Probe's Prostate Cancer Assay
August 17, 2011 / GenomeWeb Daily News - Helicos Expands Licensing Deal with Arizona Technology Enterprise
August 30, 2011 / GenomeWeb Daily News - FDA Clears Abbott's Companion Dx for Pfizer's NSCLC Drug
August 29, 2011 / GenomeWeb Daily News - NCI Kicks Off Second Stage of Clinical Proteomic Technologies for Cancer Initiative
August 26, 2011 / ProteoMonitor - Yale-Led Group Links Protein Markers to Kidney Injury in Cardiac Surgery Patients
August 26, 2011 / ProteoMonitor